ALX Oncology Holdings Inc. (ALXO)

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to transforming the lives of patients fighting cancer. Founded in 2015, the company focuses on developing therapies that block the CD47 protein, a "don't eat me" signal used by cancer cells to evade the immune system. As of 2023, Dr. Jaume Pons serves as the President and CEO, leading ALX Oncology in its innovative approach to enhancing immune response against tumors. The company is headquartered in Burlingame, California. ALX Oncology's lead product candidate, evorpacept (also known as ALX148), is designed to be used in combination with other anti-cancer agents, aiming to improve treatment efficacy by making cancer cells more susceptible to immune system attacks. While being an emerging biotech firm, specific revenue figures are not typical until products are commercialized post-clinical trials. The company's mission underscores a commitment to advancing breakthrough therapies that have the potential to significantly improve patient outcomes.